
Corbion
Corbion, the Dutch market leader in lactic acid and biobased ingredients, reported its strongest quarter in the recent run with rising sales and margins.
Published May 5, 2026 · Updated Nov 20, 2026 · by EllTec Analysis · Wave count: Lukas Köppl · ~23 min read · How to read this analysis →
Disclosure: the EllTec Analysis Tracking Portfolio currently holds no position in CRBN. (as of Nov 20, 2026)
For information and education only. Not investment advice. See the full disclaimer for details. Grafic source: TradingView.
In 60 seconds
- Fundamentals
- Corbion's third quarter 2026 was the strongest in the recent run: sales +7.6% organic and adjusted EBITDA +29.0% with an 18.8% margin, while the full-year outlook was left unchanged.
- Strength
- Market leadership in lactic acid and derivatives
- Risk
- Cyclical revenue patterns in the European chemical sector
- Premium
- The Elliott Wave part of this analysis is for subscribers: Risk Factors · Overall Assessment
Key figures
Interactive chartCorbionEURONEXT:CRBN
Switch the time frame (minutes to months), zoom, scroll and draw your own lines. The chart is provided by TradingView. Loading it transfers data such as your IP address to TradingView. Your choice is remembered in this browser. Privacy policy
More analyses in Stocks
All stock analyses →
Pfizer Inc.
Pfizer at a decision point: is the multi-decade correction over, or does the patent cliff force one last low?

Volkswagen AG
Volkswagen is in a fundamentally weak phase with collapsing operating profit and falling deliveries in China, while the share trades at an extremely low valuation.

Alibaba Group
Alibaba is China's largest e-commerce and cloud group; the analysis covers its fundamentals, valuation, macro backdrop and the long-term wave structure.
New analyses by email
EllTec Analysis Updates: a short email whenever a new analysis is published or a scenario changes. Free, unsubscribe any time.
Newsletter →